Roche Licenses Rights to Develop Assay, Companion Dx for EGFR Mutations | GenomeWeb

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Roche today announced agreements to develop a diagnostic assay for the detection of epidermal growth-factor receptor mutations and a PCR-based companion diagnostic test to identify patients with non-small cell lung cancer with EGFR-activating mutations.

In separate agreements, Roche has obtained a worldwide sub-license from Genzyme to develop the EGFR assay, and will collaborate with OSI Pharmaceuticals to develop the companion diagnostic.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

In Nucleic Acids Research this week: transcriptome patterns of Zika-infected cells, updated Comparative Toxicogenomics Database, and more.

BMJ study says that about half of former hematology-oncology regulators now work for industry.

Science should wish PhDs who leave academia well, a Nature editorial says.

New York-based doctors announce the birth of a baby boy whose parents underwent mitochondrial transfer therapy, New Scientist reports.